Amphastar Pharmaceuticals, Inc.
NASDAQ:AMPHDrug Manufacturers - Specialty & Generic
-$0.31 today
- Market cap
- $1.27B
- Beta
- 0.90
- P/E (TTM)
- 10.9
- EPS (TTM)
- $1.75
Volume 0.53M
Average 0.59M
AMPH Account Payables
Amounts the company owes suppliers for goods and services received.
Amphastar Pharmaceuticals, Inc.NASDAQ: AMPH
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables falls 32.8% from a year ago
Account payables stood at $35.5M at the end of Q1 FY2026, down 32.8% from a year earlier and up 8.9% from the prior quarter. Over 3 fiscal years it compounded at +16.7% a year.
Context
- Account payables amounted to 2.2% of total assets at the end of Q1 FY2026, down 1.1 pp from a year earlier.
- Account payables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps falling in the next quarterly balance sheet after a -32.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 32.59M USD
- Year-over-year change
- +6.8%
- 4-year CAGR
- +10.1%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 32.59M | +6.8% |
| FY2024 | 2024-12-31 | 30.51M | +20.0% |
| FY2023 | 2023-12-31 | 25.44M | +24.1% |
| FY2022 | 2022-12-31 | 20.5M | -7.7% |
| FY2021 | 2021-12-31 | 22.21M | — |
Account Payables vs competitors
How AMPH compares with its peers on the latest reported figures
- Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -32.8% is the 6th highest of 8, against a peer median of -6.0%.
- Account payables amounts to 2.2% of total assets for AMPH, versus a peer median of 6.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | ₹36.24B INR | -10.0% | +22.4% | 6.3% | |
| Jun 2026 | $2.72B USD | +8.9% | +10.3% | 6.8% | |
| Jun 2026 | $1.24B USD | -6.0% | +3.8% | 3.5% | |
| Jun 2026 | $593M USD | -5.4% | +4.8% | 2.4% | |
| Jun 2026 | $244.23M USD | -63.4% | +15.1% | 6.5% | |
| Mar 2026 | $35.5M USD | -32.8% | +16.7% | 2.2% | |
| Mar 2026 | $13.49M USD | +176.8% | +83.9% | 13.8% | |
| Mar 2026 | $6.83M USD | -61.8% | +45.0% | 0.4% | |
| Peer median (excluding AMPH) | — | -6.0% | +15.1% | 6.3% | |
Competitors are the stored peer set for AMPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 126.35M | 156.1M | 144.3M | 151.61M | 170.18M |
| Short-term Investments | 10.32M | 19.66M | 112.51M | 70.04M | 112.64M |
| Net Receivables | 78.8M | 88.8M | 115.47M | 138.04M | 143.56M |
| Inventory | 92.81M | 103.58M | 105.83M | 153.74M | 176.89M |
| Other Current Assets | 2.56M | 2.61M | 11.49M | 20.65M | 32.75M |
| Total Current Assets | 318.12M | 378.32M | 489.6M | 534.07M | 636.02M |
| Property, Plant & Equipment (Net) | 271.49M | 264.57M | 315.64M | 344.63M | 353.72M |
| Goodwill | 3.31M | 3.13M | 3.22M | 3.05M | 3.4M |
| Intangible Assets | 35.56M | 34.17M | 610.08M | 587.61M | 562.56M |
| Long-term Investments | 3.99M | 2.41M | 15.21M | 11M | 0 |
| Tax Assets | 22.4M | 38.53M | 53.25M | 71.12M | 42.46M |
| Other Non-current Assets | 16.67M | 20.86M | 25.91M | 25.99M | 31.14M |
| Total Non-current Assets | 353.41M | 363.67M | 1.02B | 1.04B | 993.28M |
| Total Assets | 671.53M | 741.99M | 1.51B | 1.58B | 1.63B |
| Account Payables | 22.21M | 20.5M | 25.44M | 30.51M | 32.59M |
| Short-term Debt | 2.2M | 3.05M | 436K | 234K | 1.64M |
| Tax Payables | 9.08M | 4.57M | 1.61M | 9.66M | 17.17M |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 23.16M | 17.55M | 0 | 0 | 0 |
| Total Current Liabilities | 103.81M | 94.86M | 225.41M | 173.76M | 158.16M |
| Long-term Debt | 74.38M | 72.84M | 589.58M | 601.63M | 608.66M |
| Deferred Tax Liabilities | 7.07M | 7.37M | 6.07M | 6.96M | 5.93M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 15.65M | 14.57M | 22.72M | 20.95M | 29.98M |
| Total Non-current Liabilities | 122.2M | 118.47M | 648.08M | 671.41M | 682.34M |
| Total Liabilities | 226.01M | 213.33M | 873.49M | 845.17M | 840.49M |
| Common Stock | 6K | 6K | 6K | 6K | 6K |
| Retained Earnings | 180.34M | 271.72M | 409.27M | 568.79M | 666.88M |
| Accumulated OCI | (6.77M) | (8.62M) | (8.48M) | (9.18M) | (5.31M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 445.52M | 528.66M | 639.42M | 732.3M | 788.81M |
| Total Debt | 104.66M | 102.58M | 623.64M | 650.55M | 656M |
| Net Debt | (21.69M) | (53.52M) | 479.35M | 498.94M | 485.83M |
Amphastar Pharmaceuticals, Inc.
NASDAQ:AMPH
Intrinsic Alpha fair value
Locked
Current Price
$29.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.